Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing hydroxychloroquine sulfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing hydroxychloroquine are listed in tablet form. No hydroxychloroquine product of any kind is listed in liquid form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Hydroxychloroquine is an antimalarial and antirheumatic medicine that a pharmacy may compound when a prescriber orders it.
Hydroxychloroquine is a 4-aminoquinoline, a hydroxylated relative of chloroquine with both antimalarial and anti-inflammatory activity. How it calms autoimmune disease is not fully known. Manufactured products are tablets, including Plaquenil (hydroxychloroquine sulfate), Sovuna and generics from several companies. The Plaquenil label indicates it for treatment of uncomplicated malaria and for malaria prophylaxis where chloroquine resistance is not reported, in adults and children, and for rheumatoid arthritis, systemic lupus erythematosus and chronic discoid lupus erythematosus in adults. A prescriber might order it compounded as an oral liquid for someone who cannot swallow tablets, or in a strength that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Plaquenil has no boxed warning, but its label lists serious risks: cardiomyopathy and QT prolongation with ventricular arrhythmias, irreversible retinal damage linked to cumulative dose and duration, severe skin reactions such as Stevens-Johnson syndrome and DRESS, worsening of psoriasis and porphyria, low blood counts, hemolysis in G6PD deficiency, muscle and nerve damage, suicidal thoughts and other psychiatric effects, and severe low blood sugar. Do not take it if you are allergic to 4-aminoquinoline drugs. It is not recommended with other drugs that prolong the QT interval, it can raise digoxin and cyclosporine levels, and MedlinePlus advises taking antacids 4 hours apart from it. The label reports no identified drug-associated risk of major birth defects, and LactMed notes international guidelines consider it acceptable during breastfeeding. Keep up with eye exams, and talk to your prescriber or pharmacist about any vision change, fainting or mood change.
Hydroxychloroquine is a 4-aminoquinoline antimalarial; its anti-inflammatory and immunomodulatory mechanism in rheumatoid arthritis and lupus is not fully known. Mean absolute oral bioavailability is 79 percent fasting, about 50 percent is bound to plasma proteins, and it distributes extensively to tissues. It is metabolized mainly by CYP2C8, CYP3A4 and CYP2D6, with desethylhydroxychloroquine the major metabolite, and terminal half-life in whole blood is 40 to 50 days with chronic dosing. Labeled indications for Plaquenil (Advanz Pharma) are uncomplicated malaria, malaria prophylaxis in areas without chloroquine resistance, and adult rheumatoid arthritis, systemic lupus and chronic discoid lupus. MedlinePlus notes use for porphyria cutanea tarda; this is not an FDA-approved indication, and the label warns of hepatotoxicity in patients with PCT. The label recommends a baseline retinal exam within the first year, annual BCVA, visual field and SD-OCT testing for higher-risk patients, and deferral of annual screening until five years of use in those without risk factors. Correct hypokalemia and hypomagnesemia, and monitor cardiac function, blood counts, glucose, muscle strength and reflexes during long-term therapy. Dosing is per prescriber. Hydroxychloroquine is not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
